scholarly journals Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs

2016 ◽  
Vol 32 (9) ◽  
pp. 595-600 ◽  
Author(s):  
Charles Blizzard ◽  
Ankita Desai ◽  
Arthur Driscoll
Keyword(s):  
Sustained Release ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs

scholarly journals Development and In Vitro-In Vivo Evaluation of a Novel Sustained-Release Loxoprofen Pellet with Double Coating Layer

Pharmaceutics ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 260 ◽  
Author(s):  
Dongwei Wan ◽  
Min Zhao ◽  
Jingjing Zhang ◽  
Libiao Luan
Keyword(s):  
Citric Acid ◽  
Drug Release ◽  
Sustained Release ◽  
Release Rate ◽  
Diffusion Rate ◽  
Immediate Release ◽  
Pharmacokinetic Studies ◽  
Release Tablet

This study aimed to develop a novel sustained release pellet of loxoprofen sodium (LXP) by coating a dissolution-rate controlling sub-layer containing hydroxypropyl methyl cellulose (HPMC) and citric acid, and a second diffusion-rate controlling layer containing aqueous dispersion of ethyl cellulose (ADEC) on the surface of a LXP conventional pellet, and to compare its performance in vivo with an immediate release tablet (Loxinon®). A three-level, three-factor Box-Behnken design and the response surface model (RSM) were used to investigate and optimize the effects of the citric acid content in the sub-layer, the sub-layer coating level, and the outer ADEC coating level on the in vitro release profiles of LXP sustained release pellets. The pharmacokinetic studies of the optimal sustained release pellets were performed in fasted beagle dogs using an immediate release tablet as a reference. The results illustrated that both the citric acid (CA) and ADEC as the dissolution- and diffusion-rate controlling materials significantly decreased the drug release rate. The optimal formulation showed a pH-independent drug release in media at pH above 4.5 and a slightly slow release in acid medium. The pharmacokinetic studies revealed that a more stable and prolonged plasma drug concentration profile of the optimal pellets was achieved, with a relative bioavaibility of 87.16% compared with the conventional tablets. This article provided a novel concept of two-step control of the release rate of LXP, which showed a sustained release both in vitro and in vivo.

Preparation and Bioavailability of Sustained-Release Doxofylline Pellets in Beagle Dogs

2008 ◽  
Vol 34 (7) ◽  
pp. 676-682 ◽  
Author(s):  
Hui-Feng Huang ◽  
Yan Lu ◽  
Hai-Bing He ◽  
Xing Tang
Keyword(s):  
Sustained Release ◽  
Beagle Dogs

Sustained release of indomethacin from chitosan granules in beagle dogs

1988 ◽  
Vol 40 (9) ◽  
pp. 642-643 ◽  
Author(s):  
SHOZO MIYAZAKI ◽  
HIDEKI YAMAGUCHI ◽  
CHIZUKO YOKOUCHI ◽  
MASAHIKO TAKADA ◽  
WEI-MIN HOU
Keyword(s):  
Sustained Release ◽  
Beagle Dogs

scholarly journals Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs

2020 ◽  
Vol 59 (6) ◽  
pp. 737-741
Author(s):  
Brian J Smith ◽  
Stephen M Kirschner ◽  
Lon V Kendall
Keyword(s):  
Sustained Release ◽  
Adult Male ◽  
Plasma Concentrations ◽  
Beagle Dogs ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Subcutaneous Dose ◽  
Cynomolgus Macaques ◽  
Animal Handling ◽  
Time Point

In cynomolgus macaques, plasma levels of sustained-release formulations of meloxicam meet or exceed efficacious concentrations for 48 to 72 h, thereby allowing less animal handling and providing more consistent efficacy than standard formulations of meloxicam. The goal of this study was to compare the pharmacokinetics of a single subcutaneous dose of a sustained-release formulation of meloxicam (Melox-SR) with those of oral (Melox-PO) and standard subcutaneous (Melox-SC) formulations dosed every 24 h for 3 consecutive days. Dogs (5 or 6 adult male Beagles) each received the following 3 treat- ments: first, Melox-SR (10 mg/mL, 0.6 mg/kg SC once), next Melox-SC (0.2 mg/kg SC once, followed by 0.1 mg/kg SC every 24 h), and finally Melox-PO (same dosage as Melox-SC), with a washout period of at least 2 wk between formulations. Blood was collected at 0 (baseline), 1, 4, 8, 12, 24, 48, and 72 h after the initial administration of each formulation for comparison of meloxicam plasma concentrations. Blood was also collected before administration and at 48 h after Melox-SR injection for CBC and chemistry analysis. Plasma concentrations (mean ± 1 SD) of Melox-SR peaked at the 1-h time point (2180 ± 359 ng/ mL), whereas those of Melox-PO (295 ± 55 ng/mL) and Melox-SC (551 ± 112 ng/mL) peaked at the 4-h time point. Melox-SR yielded significantly higher plasma concentrations than Melox-PO and Melox-SC until the 48 and 72-h time points, respec- tively. Melox-SC plasma concentrations were significantly higher than those of Melox-PO at 4, 8, 12, 24, 48 and 72 h. No lesions were noted at the Melox-SR injection sites, and Melox-SR administration was not associated with changes in the CBC and serum chemistry panels. A single 0.6-mg/kg dose of Melox-SR can yield plasma concentrations that exceed 350 ng/mL for at least 72 h in adult male dogs.

scholarly journals Pharmacokinetic studies of 1.ALPHA.,24(R)-(OH)2D3(TV-02)(5). Plasma level and excretion in beagle dogs.

1990 ◽  
Vol 5 (1) ◽  
pp. 63-69
Author(s):  
Tomohiro OHTA ◽  
Hirohide MIMURA ◽  
Masaru YAMAMOTO ◽  
Mamoru KIYOKI ◽  
Takeo OHBA ◽  
...  
Keyword(s):  
Plasma Level ◽  
Pharmacokinetic Studies ◽  
Beagle Dogs

scholarly journals Pharmacokinetic studies of phloretin in beagle dogs plasma using LC–MS/MS

2017 ◽  
Vol 29 (4) ◽  
pp. 443-447 ◽  
Author(s):  
Libin Wang ◽  
Le Mi ◽  
Tian Feng ◽  
Xueying Liu ◽  
Shengyong Zhang
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs

Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs

2011 ◽  
Vol 189 (3) ◽  
pp. 336-340 ◽  
Author(s):  
E. Lavy ◽  
U. Prise ◽  
G. Soldani ◽  
D. Neri ◽  
N. Brandriss ◽  
...  
Keyword(s):  
Sustained Release ◽  
Oral Administration ◽  
Beagle Dogs
Sign in / Sign up

Export Citation Format

Share Document